Olema Pharmaceuticals, Inc. (OLMA)

NMS – Real vaqt narxi. Valyuta: USD

10.64

+0.21 (2.01%)

Bozor ochiq: Aug 12, 2026, 11:35 AM EDT

10.44

+0.01 (0.10%)

Oldingi bozordan keyin: Aug 11, 2026, 7:36 PM EDT

11.08.2026

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.

04.08.2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock, effective as of August 3, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Olema Pharmaceuticals, Inc. (OLMA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Olema Pharmaceuticals, Inc. (OLMA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)